HPV Self-Sampling & Managing Positive HPV Results

In May 2024 the FDA approved self-collection for two HPV tests already used in cervical cancer screening — BD's Onclarity and Roche's cobas. Instead of a clinician taking a cervical sample during a pelvic exam, you collect a vaginal sample yourself with a swab or brush, in a health care setting: a primary care office, urgent care, a pharmacy, a mobile clinic.

At-home collection is not yet FDA approved in the US. Studies are running now, including NCI's SHIP trial under its Last Mile Initiative.

This matters because more than half of cervical cancers in the US occur in people who were never screened or were under-screened. For many of them, the pelvic exam itself is the barrier — because of past trauma, disability, cost, distance, or plain discomfort.

An HPV test looks for high-risk types of human papillomavirus, the virus behind nearly all cervical cancer. It does not look for cancer, and it does not look for abnormal cells. Those are separate tests, though both can sometimes be run from one sample.

• Nearly all sexually active people are infected with HPV within months to a few years of becoming sexually active. About half of those infections involve high-risk types.
• Most HPV infections clear on their own, usually within a year or two, without ever causing a problem.
• When infection does persist, it typically takes 5 to 10 years to produce precancerous changes and around 20 years to become cancer.

So a positive result means the virus was detected today. It does not tell you when you acquired it, from whom, whether a partner has it, or whether it will ever cause harm.

Not one fixed thing. Management is risk-based, and the recommendation depends on three inputs:

1. Which HPV type. Types 16 and 18 carry the highest risk and usually prompt colposcopy — a close look at the cervix with a magnifying instrument, sometimes with a small biopsy — even when the cell result is normal.
2. The cytology (Pap) result, if one was run.
3. Your screening history. A negative HPV test within the previous five years roughly halves the estimated risk, because it indicates a new infection rather than a persistent one.

Those inputs are combined into an estimated risk of high-grade precancer, and the risk band sets the step:

• Roughly 4% or higher — colposcopy
• Roughly 0.55% to under 4% — repeat testing in one year
• Roughly 0.15% to under 0.55% — return in three years

A repeat in a year is not a stall. It is the recommended action for a low-risk positive, and most such infections have cleared by the time you come back.

A self-collected sample is sufficient to run the HPV test. If it comes back positive, the next step often does require an in-person visit — a cervical sample for cytology, or a colposcopy. Ask at the time of collection what the follow-up path looks like, so the second appointment is not a surprise.

HPV vaccination prevents new infections with the types it covers. It does not clear an infection already present, and it does not cover every high-risk type. Being vaccinated does not remove the need for screening, and a positive test after vaccination is not a vaccine failure.

Many people find the year between a low-risk positive and the repeat test harder than the test itself. Two things that help: ask for your specific result in writing, including the HPV type, and ask what would change the plan. Knowing the numbers your recommendation is based on tends to make the interval feel less like being left in limbo.

• NCI — HPV and Cancer
• NCI — Cervical Cancer Screening (PDQ®) Patient Version
• ACOG — Updated Guidelines for Management of Cervical Cancer Screening Abnormalities (2019 ASCCP risk-based guidelines)
• ASCCP — Management Guidelines